

1           **SARS-CoV-2 Omicron XBB infections boost cross-variant neutralizing antibodies,**  
2           **potentially explaining the observed delay of the JN.1 wave in some Brazilian regions**

3  
4 Luis Fernando Lopez Tort<sup>a,bφ\*</sup>, Mia Ferreira de Araújo<sup>aφ</sup>, Ighor Arantes<sup>cφ</sup>, Jéssica SCC Martins<sup>a</sup>,  
5 Marcelo Gomes<sup>d,e</sup>, Felipe Cotrim de Carvalho<sup>e</sup>, Walquiria Aparecida Ferreira de Almeida<sup>e</sup>,  
6 Braulia Costa Caetano<sup>a</sup>, Luciana R. Appolinario<sup>a</sup>, Elisa Calvalcante Pereira<sup>a</sup>, BSc. Jéssica  
7 Carvalho<sup>a</sup>, Fábio Miyajima<sup>f</sup>, Gabriel Luz Wallau<sup>g,h</sup>, Felipe Gomes Naveca<sup>c,i</sup>, Pedro Alves<sup>j</sup>,  
8 Otávio Espíndola<sup>k</sup>, Patricia Brasil<sup>k</sup>, Paola Cristina Resende<sup>a‡</sup>, Gonzalo Bello<sup>c‡</sup>, and Marilda  
9 Mendonça Siqueira<sup>a‡</sup>.

10  
11 <sup>a</sup>Laboratory of Respiratory Viruses, Exanthematous and Enteroviruses and Viral Emergencies, Oswaldo Cruz  
12 Institute, Rio de Janeiro, RJ, Brazil.

13 <sup>b</sup>Laboratory of Molecular Virology, Biological Sciences Department, *CENUR Litoral Norte, Universidad de la*  
14 *República*, Salto, Uruguay.

15 <sup>c</sup>Laboratory of Arbovirus and Hemorrhagic Viruses, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil.

16 <sup>d</sup>Fiocruz, Presidency, Scientific Computing Program, Group of Analytical Methods in Epidemiological Surveillance,  
17 Rio de Janeiro, Brazil.

18 <sup>e</sup>Department of Transmissible Diseases, General Coordination of Surveillance of Covid-19, Influenza and Other  
19 Respiratory Viruses, Secretariat of Health and Environmental Surveillance, Ministry of Health, Brasília, Brazil.

20 <sup>f</sup>Analytical Competence Molecular Epidemiology Laboratory (ACME), Fundação Oswaldo Cruz (FIOCRUZ),  
21 Fortaleza, Ceará, Brazil.

22 <sup>g</sup>Department of Entomology & Bioinformatics Center, *Aggeu Magalhães* Institute, FIOCRUZ, Recife, Pernambuco,  
23 Brazil.

24 <sup>h</sup>Department of Arbovirology, Bernhard Nocht Institute for Tropical Medicine, Who Collaborating Center for  
25 Arbovirus and Hemorrhagic Fever Reference and Research. National Reference Center for Tropical Infectious  
26 Diseases, Hamburg, Germany.

27 <sup>i</sup>Laboratory of Ecology of Transmissible Diseases of Amazônia, *Leônidas e Maria Deane* Institute, FIOCRUZ,  
28 Manaus, Amazonas, Brazil.

29 <sup>j</sup>Laboratory of Immunology of Viral diseases, *René Rachou* Institute, FIOCRUZ, Belo Horizonte, Minas Gerais,  
30 Brazil.

31 <sup>k</sup>Laboratory of Clinical Research for Acute Febrile Illnesses, *Evandro Chagas* National Institute of Infectious  
32 Diseases, FIOCRUZ, Rio de Janeiro, RJ, Brazil.

33  
34 <sup>φ</sup>*These authors have contributed equally to this work.*

35 <sup>‡</sup>*These authors share the senior authorship.*

36 <sup>\*</sup>*Corresponding author:*

37 Dr. Luis Fernando Lopez Tort.

38 Laboratory of Respiratory Viruses, Exanthematous and Enteroviruses and Viral Emergencies,  
39 Oswaldo Cruz Institute, FIOCRUZ, 4365 Brasil Ave, Manguinhos, CP: 21040-360, Rio de  
40 Janeiro, RJ, Brazil. Telephone: 0055 21 25984220.

41 Email: [fernandolopezort@gmail.com](mailto:fernandolopezort@gmail.com)

42

43

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## Abstract

### *Objectives*

The SARS-CoV-2 JN.1 lineage emerged in late 2023 and quickly replaced the XBB lineages, becoming the predominant Omicron variant worldwide in 2024. We estimate the epidemiological impact of this SARS-CoV-2 lineage replacement in Brazil and we further assessed the cross-reactive neutralizing antibody (NAb) responses in a cohort of convalescent Brazilian patients infected during 2023.

### *Methods*

We analyzed the evolution of SARS-CoV-2 lineages and severe acute respiratory infection (SARI) cases in Brazil between July 2023 and March 2024. We evaluated the cross-reactive NAb responses to the JN.1 variant in a cohort of convalescent Brazilian patients, both before and after infection with XBB.1\* lineages.

### *Results*

JN.1 replaced XBB with similar temporal dynamics across all country regions, though its epidemiological impact varied between locations. The Southeastern, Southern, and Central-Western regions experienced a brief XBB wave around October 2023, shortly before the introduction of JN.1, without any immediate upsurge of SARI cases during viral lineage replacement. By contrast, the Northeastern and Northern regions did not experience an XBB wave in the latter half of 2023 and displayed a rapid surge in SARI cases driven by the emergence of the JN.1. We found that recent XBB infections in the Brazilian population significantly boosted cross-reactive NAb levels against JN.1.

### *Conclusions*

The XBB wave observed in the second half of 2023 in some Brazilian states likely acted as a booster for population immunity, providing short-term protection against JN.1 infections and delaying the rise of SARI cases in certain regions of the country.

**Keywords:** SARS-CoV-2, XBB variant, JN.1 variant, lineages evolution, Severe Acute Respiratory Infection Cases, Neutralizing Antibodies, Brazil.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## **Introduction**

In response to the decline in Coronavirus disease 2019 (COVID-19) related hospitalizations and intensive care unit admissions, and the high rates of population immunity against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the World Health Organization (WHO) has announced this disease is now an established and ongoing health issue that no longer constitutes a public health emergency of international concern [1]. However, the unceasing circulation and ongoing evolution of SARS-CoV-2 leads to the constant emergence of novel viral lineages that challenge the immune barrier established by previous infections and vaccine boosters, particularly since the emergence of the variant of concern (VOC) Omicron [1]. In the last years, immune evasion has reached a new threshold with the emergence of the Omicron BA.2 descendent lineages XBB and JN.1, which greatly reduced neutralization responses induced by both SARS-CoV-2 wild-type monovalent (wild type) and bivalent (wild type + Omicron BA.5) vaccines [3–8]. The XBB variant resulted from a recombination between two BA.2 lineages (BJ.1 and BM.1.1.1), was first identified in mid-August of 2022 and several XBB descendent lineages (XBB.1\*) dominated viral transmissions across the world in 2023 [9–11]. Another substantially mutated BA.2 lineage, the BA.2.86, emerged in August 2023 and carries more than 30 mutations in the Spike (S) protein compared with XBB and BA.2 variants [12]. BA.2.86 rapidly evolved leading to the emergence of several descendant lineages such as JN.1, that emerged in late 2023, which has only one additional mutation in the S protein (L455S) compared with BA.2.86 and it is one of the most immune-evading variants to date [13,14]. The JN.1 family (JN.1\*) reached global dominance at the beginning of 2024 and represented more than 90% of the SARS-CoV-2 lineages detected worldwide as of June 2024 [11,15].

1 In Brazil, the epidemiological scenario regarding the sequential replacements of BA.5 by  
2 XBB.1\* lineages in early 2023 and of XBB.1\* by JN.1\* lineages in late 2023, followed the same  
3 pattern observed at the global scale [16,17]. Nevertheless, the immediate epidemiological impact  
4 of the spread of JN.1\* lineages across different Brazilian regions has not been previously  
5 explored. In this study we combined data of SARS-CoV-2 sequences with information of severe  
6 acute respiratory infection (SARI) cases across different Brazilian states to investigate the  
7 potential rise in SARI cases in relation to the timing of XBB.1\* replacement by JN.1\* lineages.  
8 Moreover, we further assessed the cross-reactive neutralizing antibody (NAb) responses against  
9 JN.1 in a cohort of convalescent Brazilian patients infected with XBB.1\* lineages.

10

## 11 **Materials and Methods**

12 *Sample collection and human cohorts.* Nasopharyngeal swabs and serum samples were obtained  
13 from 29 individuals (Table S1) selected from a major study that aimed to investigate SARS-CoV-  
14 2 dynamics among patients and household contacts in a slum in Rio de Janeiro, Brazil [18,19].  
15 The cohort of volunteers analyzed in the present study is composed of 10 individuals infected  
16 with XBB.1\* lineages between January and September of 2023, including *i*) six individuals with  
17 serum samples collected 25–255 days before and 20-40 days after the infection, and *ii*) four  
18 individuals with serum samples collected only 25-30 days after infection. Moreover, serum  
19 samples from 19 individuals infected with JN.1\* lineages between January and February of  
20 2024, collected 30-70 days after infection, were also included. Nasopharyngeal swabs were used  
21 to screen for SARS-CoV-2 by real-time RT-PCR 4Plex SC2/VOC Molecular Kit (Bio-  
22 Manguinhos, Rio de Janeiro, Brazil), or TaqPath COVID-19 RT-PCR Kit (Applied Biosystems,  
23 Waltham, Massachusetts, EUA), according to the manufacturer's instructions. Viruses from

1 selected individuals were sequenced by the COVID-19 Fiocruz Genomic Surveillance Network,  
2 and all genomic and epidemiological data were uploaded to the EpiCoV™ database (Table S1)  
3 [20]. The Brazilian National Committee of Ethics in Research (CONEP) gave ethical approval  
4 for this work (protocol number: 30639420.0.0000.5262), and signed written informed consent  
5 was obtained from all participants.

6 *SARS-CoV-2 Brazilian genome sequences.* A total of 6,785 SARS-CoV-2 complete genome  
7 sequences recovered across different Brazilian states between 1<sup>st</sup> July 2023 and 31<sup>st</sup> March 2024  
8 were newly generated by the COVID-19 Fiocruz Genomic Surveillance Network. All samples  
9 had real-time RT-PCR cycling thresholds below 30, indicating elevated viral load. SARS-CoV-2  
10 genome sequences were generated using the Illumina COVIDSeq Test kit. Raw data were  
11 converted to FASTQ files at Illumina BaseSpace cloud, and consensus sequences were produced  
12 with the most up-to-date version of DRAGEN COVID LINEAGE. All genomes were evaluated  
13 for mutation calling and quality with the Nextclade 2.14.0 algorithm and were uploaded to the  
14 EpiCoV™ database of GISAID (<https://gisaid.org/>) (see the supplemental material) [21].  
15 Additionally, we downloaded all publicly available Brazilian sequences ( $n = 6,216$ ) collected  
16 between 1<sup>st</sup> July 2023 and 31<sup>st</sup> March 2024 that were submitted to the EpiCoV™ database until  
17 10 July 2024 with complete collection date/location and lineage assignment. Whole-genome  
18 consensus sequences were classified using the “Phylogenetic Assignment of Named Global  
19 Outbreak Lineages” (PANGOLIN) software v4.3 (pangolin-data version 1.21) [22].

20 *SARS-CoV-2 Isolates.* Two isolates belonging to the XBB.1.9 (EpiCoV™ accession ID:  
21 **EPI\_ISL\_18250802**) and JN.1.1 (EpiCoV™ accession ID: **EPI\_ISL\_19225686**) lineages were  
22 obtained from nasopharyngeal swabs and used as reference isolates in the Plaque Reduction  
23 Neutralization Test (PRNT) assay. Briefly, eligible SARS-CoV-2-positive samples were

1 submitted to virus isolation in Vero E6 cells at a Biosafety level 3 Laboratory, as previously  
2 described [23]. When cytopathic effect (CPE) was observed, culture supernatants were collected  
3 in working stocks and an aliquot was submitted to real-time RT-PCR followed by whole-genome  
4 sequencing for lineage confirmation. Once confirmed, the consensus sequences were deposited  
5 at the EpiCoV™ database on GISAID ([www.gisaid.org](http://www.gisaid.org)) and each SARS-CoV-2 isolate was  
6 titrated by plaque assay.

7 *PRNT Assay.* PRNT was used to determine the serum titers of SARS-CoV-2 neutralizing  
8 antibodies, as previously described by Pauvolid-Correa and colleagues [23], with some  
9 modifications. Briefly, sera were treated at 56°C for 30 min and used in PRNT in Vero cells  
10 (ATCC, CCL 81) maintained in cell culture medium supplemented with fetal bovine serum,  
11 sodium bicarbonate, antibiotics/antimycotics, and cultivated at 5% CO<sub>2</sub> atmosphere and 37°C.  
12 Serum samples were tested in duplicates in serial 2-fold dilutions (1:10 to 1:320) for their ability  
13 to neutralize 40–60 plaques forming units (PFUs) by each one of the two SARS-CoV-2 reference  
14 isolates: XBB.1.9 and JN.1.1. Sera were mixed with the respective SARS-CoV-2 isolates and  
15 incubated at 37°C for 1h. Afterward, the culture medium was removed from Vero cell  
16 monolayers on 12-well culture plates, which were inoculated with the virus-serum mixtures,  
17 incubated at 37°C for 1h, and overlaid with a pre-warmed cell culture medium containing 0.5%  
18 ultrapure agarose (Sigma-Aldrich). To ensure reproducibility between experiments and to  
19 establish a baseline for neutralization activity, each neutralization experiment included an  
20 infection control (no serum) and a reference serum. After 48h of incubation, plates were overlaid  
21 with a pre-warmed cell culture medium containing 0.5% ultrapure agarose and neutral red  
22 solution (Sigma-Aldrich) to visualize viral plaques, and after 72h, PFUs were counted through a  
23 transilluminator. The neutralization titer of a serum is calculated as the reciprocal value of the

1 highest serum dilution that reduces the number of viral plaques by 90% (PRNT<sub>90</sub>). A serum  
2 sample is considered reactive to a specific SARS-CoV-2 lineage when the PRNT<sub>90</sub> neutralization  
3 titer reaches a value of at least 10 against that isolate [24].

4 *Data on hospitalizations for SARI.* We extracted data about hospitalizations resulting from SARI  
5 attributed explicitly to SARS-CoV-2 (SARI-COVID) in Brazil during the period spanning from  
6 July 2023 to March 2024. This information was sourced from the Influenza Surveillance  
7 Information System (SIVEP-Gripe) database ([https://opendatasus.saude.gov.br/dataset?tags=](https://opendatasus.saude.gov.br/dataset?tags=SRAG)  
8 SRAG). To identify SARI cases, we utilized a set of four criteria which required individuals to  
9 exhibit: (i) fever, including self-reported cases; (ii) cough or sore throat; (iii) dyspnea or oxygen  
10 saturation levels below 95% or experiencing respiratory discomfort; and (iv) hospitalization.  
11 Once an individual meets these criteria and is admitted to a hospital for SARI, their case must be  
12 reported and recorded as a distinct entry in the SIVEP-Gripe database. Confirmation of  
13 hospitalization for SARI-COVID was contingent on a positive result from the RT-PCR test for  
14 SARS-CoV-2. For our analysis, we considered all the records within the SIVEP-Gripe database  
15 that adhered to the criteria for defining a hospitalized SARI case. We excluded records related to  
16 non-hospitalized deaths from our examination.

17 *Variant-specific SARI cases.* To estimate the number of SARS-CoV-2 infections driven by  
18 different variants, we combine the variant frequency data with the number of SARI cases over  
19 time (Figure S1). For these analyses, we included a total of 15 states from Northern (Amazonas  
20 [AM] and Para [PA]), Northeastern (Alagoas [AL], Ceara [CE], Paraiba [PB], Pernambuco [PE],  
21 Piaui [PI], Rio Grande do Norte [RN] and Sergipe [SE]), Central-Western (Goiás [GO] and  
22 Federal District [DF]), Southeastern (Minas Gerais [MG], Rio de Janeiro [RJ] and Sao Paulo  
23 [SP]) and Southern (Parana [PR], Santa Catarina [SC] and Rio Grande do Sul [RS]) regions that

1 displayed a significant number of SARI cases ( $n > 100$ ) and clearly defined wave peaks in the  
2 study period.

3 *Data analysis.* Graph representations and statistical analysis were performed using GraphPad  
4 Prism software v10.2.3 (GraphPad Software, San Diego, CA, USA). The Wilcoxon signed rank  
5 test and Mann–Whitney test were used to assess the significant difference between the data sets  
6 of PRNT<sub>90</sub> titers values obtained. A  $P$  value  $< 0.05$  was considered to be statistically significant.

7

## 8 **Results and Discussion**

9 We analyzed a total of 13,001 Brazilian SARS-CoV-2 genomes sampled across all Brazilian  
10 regions and states between 1<sup>st</sup> July 2023 and 31<sup>st</sup> March 2024 (Figure 1a and Figure S1). Viral  
11 sequences were mostly classified as XBB.1\* (63%), JN.1\* (31%), or XDR (5%) lineages. XDR  
12 is a recombinant clade between XBB.1 and JN.1 descendent lineages which harbors the S protein  
13 of JN.1 and display a transmissibility similar to that lineage and was then grouped within the  
14 family of viral lineages with a JN.1\* S protein [25]. The JN.1\* lineages were first detected in  
15 Brazil in October 2023 and achieved dominance ( $>50\%$  of cases) by January 2024. This pattern  
16 was quite homogenous across all Brazilian regions and states, except for Ceara, located in the  
17 Northeastern region, where the JN.1\* lineages already achieved dominance by November 2023  
18 (Figure 1b and Figure S2). This clear pattern of substitution of XBB.1\* by JN.1\* lineages across  
19 all Brazilian localities is consistent with the higher JN.1\* transmissibility concerning XBB.1\*  
20 lineages previously estimated in Brazil and elsewhere [13,25].

21 To assess the epidemiological consequences of the dissemination of JN.1\* lineages across  
22 different Brazilian states, we estimated the relative number of variant-specific infections by  
23 combining variant frequency data with the number of SARI-COVID cases over time. This



1 analysis revealed four major epidemic patterns (Figure 1c). In some states from Northeastern  
2 (CE, PI, PB, RN, and SE) and Northern (AM and PA) regions, the JN.1\* lineages started to  
3 circulate after a long time interval (> 6 months) of low SARI incidence and viral lineage  
4 replacement coincided with a sharp increase of SARI cases that peaked in December 2023-  
5 January 2024. In the Northeastern states of AL and PE, viral lineage replacement also coincided  
6 with a sharp increase of SARI cases in late 2023, but such a wave was driven by a mixture of  
7 both XBB.1\* and JN.1\* lineages. The XBB variant wave started a couple of weeks earlier and  
8 reached a peak somewhat larger than the JN.1 variant wave. The Northeastern state of BA  
9 displayed a wave of SARI cases driven by XBB.1\* that peaked in November 2023, shortly  
10 followed by a wave of smaller size driven by JN.1\* that extends from January to February 2024.  
11 Finally, states from Central-Western, Southeastern, and Southern regions experienced a wave of  
12 SARI cases driven by XBB.1\* that peaked around October 2023, a subsequent spread of JN.1\*  
13 lineages without an immediate upsurge of SARI cases, and a delayed wave of SARI cases driven  
14 by JN.1\* around February-March 2024.

15 This pattern observed in the Northeastern/Northern regions resembles that previously described  
16 in Brazil during replacements of B.1\* lineages by Gamma and of Delta by Omicron (BA.1),  
17 although the total number of SARI cases in the JN.1 wave was much lower than in previous  
18 waves [26–30]. Meanwhile, the pattern of lineage replacement without an upsurge of SARI cases  
19 observed in the other country regions resembles that described during the substitution of VOC  
20 Gamma by Delta in Brazil [26,31]. These findings are consistent with the notion that SARS-  
21 CoV-2 lineage replacements are primarily driven by the relative transmissibility of viral lineages,  
22 while epidemic dynamics also depend on the underlying population immunological landscape  
23 and, particularly, the proportion of susceptible hosts [2,32–35]. We hypothesized that the XBB

1 variant wave that occurred in some Brazilian regions around October 2023 boosted the  
2 population cross-immunity and generated short-term protection against JN.1 infection, thus  
3 preventing an immediate upsurge of SARI cases during lineage turnover.

4 To test this hypothesis, we investigated the NAb responses induced by XBB.1\* infections against  
5 the JN.1 variant in 10 Brazilian individuals who were longitudinally followed. As expected, a  
6 significant ( $P < 0.05$ ) and large increase in PRNT<sub>90</sub> titers (29.6-fold) was observed between pre-  
7 and post-infection sera against XBB.1 (Figure 2a). We also observed a significant ( $P < 0.05$ )  
8 increase (10.7-fold higher) in the PRNT<sub>90</sub> titers against JN.1 in post-infection sera compared  
9 with the pre-infection samples (Figure 2a). The PRNT<sub>90</sub> titers against JN.1 were 2.9-fold lower  
10 than against XBB.1 after XBB.1\* infection, while the PRNT<sub>90</sub> titers against JN.1 after JN.1\*  
11 infection were 3.5-fold higher than those obtained after XBB.1\* infection (Figure 2b). Despite  
12 this reduced neutralizing activity, neutralization of JN.1 was observed in most (90%) XBB-  
13 infected individuals analyzed. These results agree with recent studies showing a significant (~10-  
14 fold) increase in NAb responses against the JN.1 variant following XBB.1.5 vaccine booster or  
15 XBB.1\* infection [36–41]. Those studies also showed that serum titers against JN.1 were around  
16 2□ to 6□ fold lower than against XBB.1.5, depending on population immune backgrounds.

17 The epidemic pattern of SARI cases in the Southeastern/Southern/Central-Western regions  
18 reveals a minimum time interval of 4-5 months between the XBB and JN.1 wave peaks (Figure  
19 1c). This is consistent with the notion that cross-reactive immunity induced by XBB.1\*  
20 infections wanes over time, fueling a JN.1 wave of SARI cases ~4-5 months later in those  
21 regions [42,43]. Interestingly, among the 19 individuals from the Southeastern state of RJ  
22 infected with the JN.1 variant analyzed in our study, seven had a documented previous SARS-  
23 CoV-2 infection (Table S1). This includes three individuals who were infected during the period

1 of XBB dominance between March and September 2023. The time interval between previous  
2 XBB infections and JN.1 reinfections ranges between 5.3 and 10.8 months. These findings  
3 corroborate that individuals previously infected with XBB.1\* lineages could be reinfected with  
4 JN.1\* lineages and further support a minimum time interval of about five months between  
5 successive infections by those Omicron lineages in the Brazilian population immune landscape.  
6 Despite the small number of subjects analyzed, our findings support that XBB.1\* infections  
7 produced substantial cross-reactive NAb responses against the JN.1 variant in the Brazilian  
8 immune background. The precise level of NAb required for protection against JN.1 infection is  
9 difficult to estimate, but some evidence supports that such cross-reactive responses induced by  
10 XBB may be protective. A recent report showed that immunity provided by natural infection  
11 against reinfection with JN.1 was strong (83% effectiveness) among those who were infected  
12 within the last six months with variants such as XBB.1\*[44]. Other studies also showed that  
13 XBB.1.5 monovalent mRNA vaccine booster conferred some protection against symptomatic  
14 infections and hospitalizations caused by the JN.1 variant [45–49]. In Brazil, the XBB.1.5  
15 monovalent mRNA vaccine was first introduced by the end of May 2024 [50]. Our findings,  
16 along with previous studies, emphasize the importance of boosters with updated XBB.1.5  
17 monovalent vaccines to enhance immune responses and reduce onward transmission of the JN.1  
18 variant currently prevalent in Brazil, particularly in priority groups of the population.  
19 Our study has some limitations. First, we estimated the relative number of variant-specific  
20 infections assuming that SARS-CoV-2 genomic surveillance was random and truly reflected the  
21 variant frequency within states and that the infection-hospitalization ratio (SARI cases/total  
22 cases) was the same for different Omicron variants. Second, due to the small sample size of  
23 XBB-infected individuals, we could not assess the potential impact of age or immune

1 background (history of infections and vaccinations) on neutralization efficiency. XBB-infected  
2 individuals' ages range between 40 and 89 (Table S1), pointing out that cross-reactive responses  
3 were not restricted to young adults. Moreover, all XBB-infected individuals included in our  
4 study were fully vaccinated (monovalent wild-type vaccines) and a significant fraction (70%)  
5 also have a documented previous infection (Table S1), thus indicating that hybrid immunity was  
6 an important component of the immune background of the studied population. Third, serum  
7 samples were collected within two months post XBB.1\* infection and we do not have  
8 information about cross-reactive neutralization efficiency against JN.1 after longer periods since  
9 infection.

10

## 11 **Conclusions**

12 The JN.1\* lineages consistently replaced the XBB.1\* lineages circulating in all Brazilian states  
13 since late 2023 but with variable epidemiological impact across regions. In those Brazilian states  
14 that experienced a XBB variant wave in the second half of 2023, shortly before the introduction  
15 of JN.1, lineage replacement occurred without a concurrent rise in the number of SARI cases. By  
16 contrast, Brazilian states without a recent XBB variant wave in the second half of 2023  
17 experienced an upsurge of SARI cases concurrent with the expansion of the JN.1 variant. Recent  
18 infections with XBB.1\* lineages induce a considerable production of cross-reactive NAb that are  
19 effective against JN.1 in the Brazilian population's immune background. Together, these results  
20 support the notion that the XBB variant wave observed in the second half of 2023 in some  
21 Brazilian states probably acted as a natural booster of the population immunity, providing short-  
22 term protection against JN.1 infections and delaying the rise of SARI cases in those country  
23 regions.

1

## 2 **Data Availability**

3 This study's conclusions derive from examining 13,001 SARS-CoV-2 genomes from Brazil,  
4 made publicly accessible via the EpiCoV™ database from GISAID. These genomes were  
5 collected after July 1<sup>st</sup>, 2023, and submissions were recorded until March 31<sup>st</sup>, 2024. The data  
6 can be accessed at <https://doi.org/10.55876/gis8.240719ev>.

7

## 8 **Acknowledgments**

9 We would like to thank the Biosafety Laboratory Level 3 platform (BSL3) at Pavilhão *Helio*  
10 *Peggy Pereira*, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.

11

## 12 **Funding**

13 Funding support from *Carlos Chagas Filho* Foundation for Research Support in the State of Rio  
14 de Janeiro (FAPERJ) (FAPERJ E-26/211.125/2021), National Council for Scientific and  
15 Technological Development (CNPq), Ministry of Science, Technology and Innovations (MCTI)  
16 and the Latin American Biotechnology Center (CABBIO) (CNPq/MCTI N° 17/2021,  
17 423857/2021-5). P.C.R. had support from CNPq (Productivity fellowship 311759/2022-0). I.A.  
18 had support from FAPERJ (grant SEI-260003/019669/2022). G.L.W. had support from CNPq  
19 (Productivity fellowship 307209/2023-7). P.B. had support from FAPERJ (E-26/200.935/2022)  
20 and CNPq (311562/2021-3).

21

## 22 **Declaration of Competing Interest**

23 The authors declare that they have no conflict of interest.

1

## 2 **Figures Legends**

3 **Figure 1. Space-time evolution of major SARS-CoV-2 variants and variant-specific SARI**  
4 **cases in Brazil between July 2023 and March 2024. a)** The map depicts Brazil's regions and  
5 states, highlighting the Southeastern (SE), Southern (S), Central-Western (CW), Northeastern  
6 (NE), and Northern (N) regions in distinct colors as indicated in the legend at the bottom. The  
7 state of Ceará (CE) is highlighted in red. Each Brazilian state is labeled with its two-letter  
8 abbreviation. **b)** Temporal fluctuations in the relative prevalence of XBB.1\* and JN.1\*+XDR  
9 lineages across Brazilian regions. **c)** Estimated number of SARI cases caused by SARS-CoV-2  
10 XBB.1\* and JN.1\*+XDR lineages through time across selected Brazilian states from  
11 Southeastern (MG, RJ, and SP), Southern (PR, SC, and RS), Northeastern (AL, BA, CE, PB, PE,  
12 PI, RN, and SE) and Northern (AM and PA) regions. States from the same region showing a  
13 similar pattern of temporal fluctuations of SARS-CoV-2 lineages (**Figure S2**) and SARI cases  
14 (**Figure S3**) were grouped for visual clarity. The Brazilian map was generated with the ggplot2  
15 [51], sf [52], and geobr [53] R packages.

16

17 **Figure 2. Neutralizing antibodies titers against XBB.1 and JN.1 variants of SARS-CoV-2 in**  
18 **Brazilian individuals who experienced an infection with XBB.1\* or JN.1\* lineages. a)**  
19 Neutralizing antibodies activity was measured by 90% plaque reduction neutralization titers  
20 (PRNT90) against XBB.1 and JN.1 variants in serum samples from a cohort of volunteers (n = 6)  
21 that were infected with XBB.1\* lineages. Paired serum samples collected before infection -  
22 XBB(BI)- and after infection with XBB.1\* -XBB(PI)- were tested for each patient. **b)** PRNT90  
23 against XBB.1 and/or JN.1 variants in a set of serum samples from individuals infected with  
24 XBB.1\* (n = 10) or JN.1\* (n = 19) lineages. Samples were collected at 25–255 days before

1 infection (BI) and 20-70 days post-infection (PI). y-axis shows the Log<sub>10</sub> PRNT<sub>90</sub> values. Fold-  
2 change in the Geometric mean titers (GMT) values and statistical significance are shown.  
3 Wilcoxon signed-rank test (A) and Mann–Whitney test (B) were used to calculate the p-values.  
4 PRNT<sub>90</sub> below the limit of detection ( < 10) were set to 1. XBB(BI)-XBB = sera obtained BI  
5 with XBB.1\* and tested against XBB.1. XBB(PI)-XBB = sera PI with XBB.1\* and tested  
6 against XBB.1. XBB(BI)-JN.1 = sera obtained BI with XBB.1\* and tested against JN.1.  
7 XBB(PI)-JN.1 = sera obtained PI with XBB.1\* and tested against JN.1, JN.1(PI)-JN.1 = sera  
8 obtained PI with JN.1\* and tested against JN.1. The bars are color-coded based on the isolate  
9 used in each category, with blue representing XBB\* isolates and orange for JN.1 isolates. PI sera  
10 bars are depicted with a dotted pattern.

11

12

## 13 **References**

14 [1] WHO (2023). Statement on the fifteenth meeting of the IHR (2005) Emergency Committee  
15 on the COVID-19 pandemic. [https://www.who.int/europe/news/item/05-05-2023-statement-on-](https://www.who.int/europe/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)  
16 [the-fifteenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-](https://www.who.int/europe/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)  
17 [regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/europe/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic) [accessed July 4, 2024].

18 [2] Markov P V., Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The  
19 evolution of SARS-CoV-2. *Nat Rev Microbiol.* 2023;21(6):361–79.  
20 <https://doi.org/10.1038/s41579-023-00878-2>

21 [3] Tan CW, Zhu F, Chia WN, Young BE, Yeoh AYY, Althaus T, et al. Distinctive serotypes of  
22 SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals. *hLife*  
23 2023;1(1):26–34. <https://doi.org/10.1016/j.hlife.2023.07.002>

- 1 [4] [preprint] Bekliz M, Essaidi-Laziosi M, Adea K, Hosszu-Fellous K, Alvarez C, Bellon M, et  
2 al. Immune escape of Omicron lineages BA.1, BA.2, BA.5.1, BQ.1, XBB.1.5, EG.5.1 and JN.1.1  
3 after vaccination, infection and hybrid immunity. bioRxiv 2024.02.14.579654.  
4 <https://doi.org/10.1101/2024.02.14.579654>
- 5 [5] Favresse J, Gillot C, Cabo J, David C, Dogné JM, Douxfils J. Neutralizing antibody response  
6 to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. Int J  
7 Infect Dis. 2024;143:107028. <https://doi.org/10.1016/j.ijid.2024.107028>
- 8 [6] Jeworowski LM, Mühlemann B, Walper F, Schmidt ML, Jansen J, Krumbholz A, et al.  
9 Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023.  
10 Eurosurveillance 2024;29(2):2300740. <https://doi.org/10.2807/1560-7917.es.2024.29.2.2300740>
- 11 [7] Wang X, Jiang S, Ma W, Zhang Y, Wang P. Robust neutralization of SARS-CoV-2 variants  
12 including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. Signal Transduct  
13 Target Ther.2024;9(1):123. <https://doi.org/10.1038/s41392-024-01849-6>
- 14 [8] Li P, Liu Y, Faraone JN, Hsu CC, Chamblee M, Zheng YM, et al. Distinct patterns of SARS-  
15 CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. mBio  
16 2024;15(5):e0075124. <https://doi.org/10.1128/mbio.00751-24>
- 17 [9] Yue C, Song W, Wang L, Jian F, Chen X, Gao F, et al. ACE2 binding and antibody evasion  
18 in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23(3):278–80.  
19 [https://doi.org/10.1016/s1473-3099\(23\)00010-5](https://doi.org/10.1016/s1473-3099(23)00010-5)
- 20 [10] Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, et al. Virological characteristics of  
21 the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat  
22 Commun. 2023;14(1):2800. <https://doi.org/10.1038/s41467-023-38435-3>



- 1 [11] GISAID Initiative (2024). Lineage Frequency. EpiCoV™. Accessed July 4, 2024.  
2 <https://gisaid.org>
- 3 [12] Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z, et al. Transmissibility, infectivity,  
4 and immune evasion of the SARS-CoV-2 BA.2.86 variant. *Lancet Infect Dis.* 2023;23(11):e460–  
5 1. [https://doi.org/10.1016/s1473-3099\(23\)00575-3](https://doi.org/10.1016/s1473-3099(23)00575-3)
- 6 [13] Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Hinay Jr AA, Chen L, et al. Virological  
7 characteristics of the SARS-CoV-2 JN.1 variant. *Lancet Infect Dis.* 2024;24(2):e82.  
8 [https://doi.org/10.1016/s1473-3099\(23\)00813-7](https://doi.org/10.1016/s1473-3099(23)00813-7)
- 9 [14] Zhang L, Dopfer-Jablonka A, Cossmann A, Stankov M V., Graichen L, Moldenhauer AS, et  
10 al. Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization  
11 evasion. *iScience.* 2024;27(6):109904. <https://doi.org/10.1016/j.isci.2024.109904>  
12
- 13 [15] Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, et al. Distinct evolution of  
14 SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and  
15 antibody evasion. *Nat Commun.* 2024;15(1):2254. <https://doi.org/10.1038/s41467-024-46490-7>
- 16 [16] Arantes I, Gomes M, Ito K, Sarafim S, Gräf T, Miyajima F, et al. Spatiotemporal dynamics  
17 and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.  
18 Ludert JE, editor. *Microbiol Spectr.* 2024;12(3):e0383123.  
19 <https://doi.org/10.1128/spectrum.03831-23>
- 20 [17] FIOCRUZ (2024). Oswaldo Cruz Foundation. Fiocruz’s Genomics Network. Dashboard.  
21 SARS-CoV-2 Genomic Surveillance in Brazil. Accessed July 4, 2024.  
22 <https://www.genomahcov.fiocruz.br/dashboard-en/>

- 1 [18] Lugon P, Fuller T, Damasceno L, Calvet G, Resende PC, Matos AR, et al. SARS-CoV-2  
2 infection dynamics in children and household contacts in a slum in Rio de Janeiro. *Pediatrics*  
3 2021; 148(1):e20211050182. <https://doi.org/10.1542/peds.2021-050182>
- 4 [19] Fernanda Borges da Silva M, Guaraldo L, Ferreira Pinto Santos H, Soares Bastos L, Lema  
5 Suarez Penetra S, Campos Vargas de Moraes I, et al. Cohort profile: follow-up of a household  
6 cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil. *Cad. Saúde*  
7 *Pública* 2024;40(7):e00152023. <https://doi.org/10.1590/0102-311XEN152023>
- 8 [20] FIOCRUZ (2021). SARS-CoV-2 Genomic surveillance in Brazil. Accessed July 4, 2024.  
9 <https://www.genomahcov.fiocruz.br/en/>
- 10 [21] Aksamentov I, Roemer C, Hodcroft E, Neher R. Nextclade: clade assignment, mutation  
11 calling and quality control for viral genomes. *J Open Source Softw.* 2021;6(67):3773.  
12 <https://doi.org/10.21105/joss.03773>
- 13 [22] O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of  
14 epidemiological lineages in an emerging pandemic using the pangolin tool. *Virus Evol.*  
15 2021;7(2):veab064. <https://doi.org/10.1093/ve/veab064>
- 16 [23] Pauvolid-Corrêa A, Caetano BC, MacHado AB, Ferreira MA, Valente N, Neves TK, et al.  
17 Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later  
18 emerged variants of concern. *Biol Methods Protoc.* 2022;7(1):bpac021.  
19 <https://doi.org/10.1093/biomethods/bpac021>
- 20 [24] Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, et al.  
21 Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. *Indian J Med Res.*  
22 2020;152(1):82–7. [https://doi.org/10.4103/ijmr.ijmr\\_2382\\_20](https://doi.org/10.4103/ijmr.ijmr_2382_20)

- 1 [25] [preprint] Arantes I, Ito K, Gomes M, Cotrim De Carvalho F, Ferreira De Almeida WA,  
2 Khouri R, et al. Rapid spread of the SARS-CoV-2 Omicron XDR lineage derived from  
3 recombination between XBB and BA.2.86 subvariants circulating in Brazil in late 2023. *medRxiv*  
4 2024. Available from: <https://doi.org/10.1101/2024.05.07.24306998>
- 5 [26] Arantes I, Bello G, Nascimento V, Souza V, da Silva A, Silva D, et al. Comparative  
6 epidemic expansion of SARS-CoV-2 variants Delta and Omicron in the Brazilian State of  
7 Amazonas. *Nat Commun.* 2023;14(1):2048. <https://doi.org/10.1038/s41467-023-37541-6>
- 8 [27] Arantes I, Gomes Naveca F, Gräf T, Miyajima F, Faoro H, Luz Wallau G, et al. Emergence  
9 and Spread of the SARS-CoV-2 Variant of Concern Delta across Different Brazilian Regions.  
10 *Microbiol Spectr.* 2022;10(5):e0264121. <https://doi.org/10.1128/spectrum.02641-21>
- 11 [28] Naveca FG, Nascimento V, de Souza VC, Corado A de L, Nascimento F, Silva G, et al.  
12 COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1  
13 emergence. *Nat Med.* 2022;27(7):1230–8. <https://doi.org/10.1038/s41591-021-01378-7>
- 14 [29] Gräf T, Bello G, Naveca FG, Gomes M, Cardoso VLO, da Silva AF, et al. Phylogenetic-  
15 based inference reveals distinct transmission dynamics of SARS-CoV-2 lineages Gamma and P.2  
16 in Brazil. *iScience* 2022;25(4):104156. <https://doi.org/10.1016/j.isci.2022.104156>
- 17 [30] Faria NR, Mellan TA, Whittaker C, Claro IM, da Candido DS, Mishra S, et al. Genomics  
18 and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*  
19 2022;372(6544):815–821. <https://doi.org/10.1126/science.abh2644>
- 20 [31] Giovanetti M, Fonseca V, Wilkinson E, Tegally H, San EJ, Althaus CL, et al. Replacement  
21 of the Gamma by the Delta variant in Brazil: Impact of lineage displacement on the ongoing  
22 pandemic. *Virus Evol.* 2022;8(1):veac024. <https://doi.org/10.1093/ve/veac024>

- 1 [32] Meijers M, Ruchnewitz D, Eberhardt J, Łuksza M, Lässig M. Population immunity predicts  
2 evolutionary trajectories of SARS-CoV-2. *Cell* 2023;186(23):5151–5164.  
3 <https://doi.org/10.1016/j.cell.2023.09.022>
- 4 [33] Bushman M, Kahn R, Taylor BP, Lipsitch M, Hanage WP. Population impact of SARS-  
5 CoV-2 variants with enhanced transmissibility and/or partial immune escape. *Cell*  
6 2021;184(26):6229–6242. <https://doi.org/10.1016/j.cell.2021.11.026>
- 7 [34] Dyson L, Hill EM, Moore S, Curran-Sebastian J, Tildesley MJ, Lythgoe KA, et al. Possible  
8 future waves of SARS-CoV-2 infection generated by variants of concern with a range of  
9 characteristics. *Nat Commun.* 2021;12(1):5730. <https://doi.org/10.1038/s41467-021-25915-7>
- 10 [35] Gabriela M, Gomes M, Ferreira MU, Corder RM, King JG, Souto-Maior C, et al. Individual  
11 variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. *J*  
12 *Theor Biol.* 2022;540:111063. <https://doi.org/10.1016/j.jtbi.2022.111063>
- 13 [36] Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, et al. Interim Report  
14 of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus  
15 2 XBB-Containing Vaccines. *J Infect Dis.* 2024;230(2):e279–e286.  
16 <https://doi.org/10.1093/infdis/jiae067>
- 17 [37] Huu Nguyenla X, Bates TA, Trank-Greene M, Wahedi M, Tafesse FG, Curlin M. Humoral  
18 Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine. *Emerg Infect Dis.*  
19 2024;30(6):1282–1283. <https://doi.org/10.3201/eid3006.240051>
- 20 [38] Springer DN, Camp J V., Aberle SW, Deutsch J, Lammel O, Weseslindtner L, et al.  
21 Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-  
22 vaccination and infection. *J Med Virol.* 2024;96(7):e29801. <https://doi.org/10.1002/jmv.29801>

- 1 [39] Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent  
2 mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.  
3 *Cell Host Microbe*. 2024;32(3):315–321. <https://doi.org/10.1016/j.chom.2024.01.014>
- 4 [40] He X, Yu J, Jiang J, Liu J, Qi Q, Liu D, et al. Heterogeneous hybrid immunity against  
5 Omicron variant JN.1 at 11 months following breakthrough infection. *Signal Transduct Target*  
6 *Ther*. 2024;9(1):180. <https://doi.org/10.1038/s41392-024-01898-x>
- 7 [41] [preprint] Abul Y, Nugent C, Vishnepolskiy I, Wallace T, Dickerson E, Holland L, et al.  
8 Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5  
9 vaccination in nursing home residents. *medRxiv* 2024.  
10 <https://doi.org/10.1101/2024.03.21.24303684>
- 11 [42] Wang X, Zhang M, Wei K, Li C, Yang J, Jiang S, et al. Longitudinal Analysis of Humoral  
12 and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB  
13 Breakthrough Infection and BA.5/BF.7-XBB Reinfection. *Vaccines (Basel)* 2024;12(5):464.  
14 <https://doi.org/10.3390/vaccines12050464>
- 15 [43] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing  
16 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2  
17 infection. *Nat Med*. 202;27(7):1205–11. <https://doi.org/10.1038/s41591-021-01377-8>
- 18 [44] Chemaitelly H, Coyle P, Ali M, Kacem B, Ayoub HH, Tang P, et al. Protection of natural  
19 infection against reinfection with SARS-CoV-2 JN.1 variant. *J Travel Med*.  
20 2024;31(4):taae053. <https://doi.org/10.1093/jtm/taae053>
- 21 [45] Link-Gelles R, Allison ;, Ciesla A, Mak J, Miller JD, Silk BJ, et al. MMWR, Early  
22 Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness  
23 Against Symptomatic SARS-CoV-2 Infection Attributable to Co-circulating Omicron Variants

1 Among Immunocompetent Adults — Increasing Community Access to Testing Program, United  
2 States, September 2023 – January 2024. *MMWR Morb Mortal Wkly Rep.* 2024;73(4):77–83.  
3 <https://doi.org/10.15585/mmwr.mm7304a2>

4 [46] [preprint] Tartof SY, Slezak JM, Frankland TB, Puzniak L, Hong V, Ackerson BK, et al.  
5 BNT162b2 XBB1.5-adapted Vaccine and COVID-19 Hospital Admissions and Ambulatory  
6 Visits in US Adults. *medRxiv* 2023. <https://doi.org/10.1101/2023.12.24.23300512>

7 [47] [preprint] Nunes B, Humphreys J, Nicolay N, Braeye T, Van I, Holm Hansen C, et al.  
8 Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths  
9 during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A  
10 VEBIS-EHR Network Study 3. *medRxiv* 2024. <https://doi.org/10.1101/2024.07.04.24309832>

11 [48] [preprint] Ma KC, Surie D, Luring AS, Martin ET, Leis AM, Papalambros MPH L, et al.  
12 Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against  
13 SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of  
14 Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024. *medRxiv*  
15 2024. <https://doi.org/10.1101/2024.06.04.24308470>

16 [49] Chong C, Wee LE, Jin X, Zhang M, Malek MIA, Ong B, et al. Risks of SARS-CoV-2 JN.1  
17 infection and COVID-19 associated emergency-department (ED) visits/hospitalizations  
18 following updated boosters and prior infection: a population-based cohort study. *Clin Infect Dis.*  
19 2024:ciae339. <https://doi.org/10.1093/cid/ciae339>

20 [50] Ministry of Health of Brazil (2024). Posted news in the web site of the Ministry of Health of  
21 Brazil in 24 May 2024. Ministry of Health launches new vaccination campaign against Covid-  
22 19. Accessed July 4, 2024. <https://www.gov.br/saude/pt->

1 [br/assuntos/noticias/2024/maio/ministerio-da-saude-lanca-nova-campanha-de-vacinacao-contra-](https://br.assuntos/noticias/2024/maio/ministerio-da-saude-lanca-nova-campanha-de-vacinacao-contra-covid-19)  
2 [covid-19](https://br.assuntos/noticias/2024/maio/ministerio-da-saude-lanca-nova-campanha-de-vacinacao-contra-covid-19)

3 [51] Wickham H (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New  
4 York. ISBN 978-3-319-24277-4. Accessed July 4, 2024. <https://ggplot2.tidyverse.org>
















5 [52] Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. *The R*  
6 *Journal* 2018;10(1):439–46. <https://journal.r-project.org/archive/2018/RJ-2018-009/index.html>

7 [53] Pereira RHM GC et al. geobr: LS of OSDS of BrazilG repository. 2019. Accessed July 4,  
8 2024. <https://github.com/ipeaGIT/geobr>


9

10

11

**a****b****S****CW****NE – CE****NE – Others****N****c****RJ + SP + MG (SE)****PR + SC + RS (S)****DF + GO (CW)****BA (NE)****AL + PE (NE)****CE (NE)****PB + PI + RN + SE (NE)****AM + PA (N)**



**a****b**